Parkinson's disease, cortical dysfunction, and alpha‐synuclein
Identifieur interne : 000204 ( Main/Exploration ); précédent : 000203; suivant : 000205Parkinson's disease, cortical dysfunction, and alpha‐synuclein
Auteurs : John N. Caviness [États-Unis] ; Lih-Fen Lue [États-Unis] ; Thomas G. Beach [États-Unis] ; Joseph G. Hentz [États-Unis] ; Charles H. Adler [États-Unis] ; Lucia Sue [États-Unis] ; Ramin Sadeghi [États-Unis] ; Erika Driver-Dunckley [États-Unis] ; Virgilio G. Evidente [États-Unis] ; Marwan N. Sabbagh [États-Unis] ; Holly A. Shill [États-Unis] ; Douglas G. Walker [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-07.
English descriptors
- KwdEn :
Abstract
The ability to understand how Parkinson's disease neurodegeneration leads to cortical dysfunction will be critical for developing therapeutic advances in Parkinson's disease dementia. The overall purpose of this project was to study the small‐amplitude cortical myoclonus in Parkinson's disease as an in vivo model of focal cortical dysfunction secondary to Parkinson's disease neurodegeneration. The objectives were to test the hypothesis that cortical myoclonus in Parkinson's disease is linked to abnormal levels of α‐synuclein in the primary motor cortex and to define its relationship to various biochemical, clinical, and pathological measures. The primary motor cortex was evaluated for 11 Parkinson's disease subjects with and 8 without electrophysiologically confirmed cortical myoclonus (the Parkinson's disease + myoclonus group and the Parkinson's disease group, respectively) who had premortem movement and cognitive testing. Similarly assessed 9 controls were used for comparison. Measurements for α‐synuclein, Aβ‐42 peptide, and other biochemical measures were made in the primary motor cortex. A 36% increase in α‐synuclein was found in the motor cortex of Parkinson's disease + myoclonus cases when compared with Parkinson's disease without myoclonus. This occurred without significant differences in insoluble α‐synuclein, phosphorylated to total α‐synuclein ratio, or Aβ‐42 peptide levels. Higher total motor cortex α‐synuclein levels significantly correlated with the presence of cortical myoclonus but did not correlate with multiple clinical or pathological findings. These results suggest an association between elevated α‐synuclein and the dysfunctional physiology arising from the motor cortex in Parkinson's disease + myoclonus cases. Alzheimer's disease pathology was not associated with cortical myoclonus in Parkinson's disease. Cortical myoclonus arising from the motor cortex is a model to study cortical dysfunction in Parkinson's disease. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23697
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease, cortical dysfunction, and alpha‐synuclein</title><author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name></author><author><name sortKey="Lue, Lih En" sort="Lue, Lih En" uniqKey="Lue L" first="Lih-Fen" last="Lue">Lih-Fen Lue</name></author><author><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G." last="Beach">Thomas G. Beach</name></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name></author><author><name sortKey="Sue, Lucia" sort="Sue, Lucia" uniqKey="Sue L" first="Lucia" last="Sue">Lucia Sue</name></author><author><name sortKey="Sadeghi, Ramin" sort="Sadeghi, Ramin" uniqKey="Sadeghi R" first="Ramin" last="Sadeghi">Ramin Sadeghi</name></author><author><name sortKey="Driver Unckley, Erika" sort="Driver Unckley, Erika" uniqKey="Driver Unckley E" first="Erika" last="Driver-Dunckley">Erika Driver-Dunckley</name></author><author><name sortKey="Evidente, Virgilio G" sort="Evidente, Virgilio G" uniqKey="Evidente V" first="Virgilio G." last="Evidente">Virgilio G. Evidente</name></author><author><name sortKey="Sabbagh, Marwan N" sort="Sabbagh, Marwan N" uniqKey="Sabbagh M" first="Marwan N." last="Sabbagh">Marwan N. Sabbagh</name></author><author><name sortKey="Shill, Holly A" sort="Shill, Holly A" uniqKey="Shill H" first="Holly A." last="Shill">Holly A. Shill</name></author><author><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G." last="Walker">Douglas G. Walker</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:144E863BBEAB2309251E849269B1DE105DB99D42</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23697</idno><idno type="url">https://api.istex.fr/document/144E863BBEAB2309251E849269B1DE105DB99D42/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002187</idno><idno type="wicri:Area/Main/Curation">001E78</idno><idno type="wicri:Area/Main/Exploration">000204</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease, cortical dysfunction, and alpha‐synuclein</title><author><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Lue, Lih En" sort="Lue, Lih En" uniqKey="Lue L" first="Lih-Fen" last="Lue">Lih-Fen Lue</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G." last="Beach">Thomas G. Beach</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Civin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sue, Lucia" sort="Sue, Lucia" uniqKey="Sue L" first="Lucia" last="Sue">Lucia Sue</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Civin Laboratory of Neuropathology, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sadeghi, Ramin" sort="Sadeghi, Ramin" uniqKey="Sadeghi R" first="Ramin" last="Sadeghi">Ramin Sadeghi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Driver Unckley, Erika" sort="Driver Unckley, Erika" uniqKey="Driver Unckley E" first="Erika" last="Driver-Dunckley">Erika Driver-Dunckley</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Evidente, Virgilio G" sort="Evidente, Virgilio G" uniqKey="Evidente V" first="Virgilio G." last="Evidente">Virgilio G. Evidente</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sabbagh, Marwan N" sort="Sabbagh, Marwan N" uniqKey="Sabbagh M" first="Marwan N." last="Sabbagh">Marwan N. Sabbagh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cleo Roberts Clinical Research Center, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Shill, Holly A" sort="Shill, Holly A" uniqKey="Shill H" first="Holly A." last="Shill">Holly A. Shill</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cleo Roberts Clinical Research Center, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G." last="Walker">Douglas G. Walker</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-07">2011-07</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1436">1436</biblScope><biblScope unit="page" to="1442">1442</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">144E863BBEAB2309251E849269B1DE105DB99D42</idno><idno type="DOI">10.1002/mds.23697</idno><idno type="ArticleID">MDS23697</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>alpha‐synuclein</term><term>cortex</term><term>dementia</term><term>myoclonus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The ability to understand how Parkinson's disease neurodegeneration leads to cortical dysfunction will be critical for developing therapeutic advances in Parkinson's disease dementia. The overall purpose of this project was to study the small‐amplitude cortical myoclonus in Parkinson's disease as an in vivo model of focal cortical dysfunction secondary to Parkinson's disease neurodegeneration. The objectives were to test the hypothesis that cortical myoclonus in Parkinson's disease is linked to abnormal levels of α‐synuclein in the primary motor cortex and to define its relationship to various biochemical, clinical, and pathological measures. The primary motor cortex was evaluated for 11 Parkinson's disease subjects with and 8 without electrophysiologically confirmed cortical myoclonus (the Parkinson's disease + myoclonus group and the Parkinson's disease group, respectively) who had premortem movement and cognitive testing. Similarly assessed 9 controls were used for comparison. Measurements for α‐synuclein, Aβ‐42 peptide, and other biochemical measures were made in the primary motor cortex. A 36% increase in α‐synuclein was found in the motor cortex of Parkinson's disease + myoclonus cases when compared with Parkinson's disease without myoclonus. This occurred without significant differences in insoluble α‐synuclein, phosphorylated to total α‐synuclein ratio, or Aβ‐42 peptide levels. Higher total motor cortex α‐synuclein levels significantly correlated with the presence of cortical myoclonus but did not correlate with multiple clinical or pathological findings. These results suggest an association between elevated α‐synuclein and the dysfunctional physiology arising from the motor cortex in Parkinson's disease + myoclonus cases. Alzheimer's disease pathology was not associated with cortical myoclonus in Parkinson's disease. Cortical myoclonus arising from the motor cortex is a model to study cortical dysfunction in Parkinson's disease. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Caviness, John N" sort="Caviness, John N" uniqKey="Caviness J" first="John N." last="Caviness">John N. Caviness</name></region><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><name sortKey="Beach, Thomas G" sort="Beach, Thomas G" uniqKey="Beach T" first="Thomas G." last="Beach">Thomas G. Beach</name><name sortKey="Driver Unckley, Erika" sort="Driver Unckley, Erika" uniqKey="Driver Unckley E" first="Erika" last="Driver-Dunckley">Erika Driver-Dunckley</name><name sortKey="Evidente, Virgilio G" sort="Evidente, Virgilio G" uniqKey="Evidente V" first="Virgilio G." last="Evidente">Virgilio G. Evidente</name><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G." last="Hentz">Joseph G. Hentz</name><name sortKey="Lue, Lih En" sort="Lue, Lih En" uniqKey="Lue L" first="Lih-Fen" last="Lue">Lih-Fen Lue</name><name sortKey="Sabbagh, Marwan N" sort="Sabbagh, Marwan N" uniqKey="Sabbagh M" first="Marwan N." last="Sabbagh">Marwan N. Sabbagh</name><name sortKey="Sadeghi, Ramin" sort="Sadeghi, Ramin" uniqKey="Sadeghi R" first="Ramin" last="Sadeghi">Ramin Sadeghi</name><name sortKey="Shill, Holly A" sort="Shill, Holly A" uniqKey="Shill H" first="Holly A." last="Shill">Holly A. Shill</name><name sortKey="Sue, Lucia" sort="Sue, Lucia" uniqKey="Sue L" first="Lucia" last="Sue">Lucia Sue</name><name sortKey="Walker, Douglas G" sort="Walker, Douglas G" uniqKey="Walker D" first="Douglas G." last="Walker">Douglas G. Walker</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000204 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000204 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:144E863BBEAB2309251E849269B1DE105DB99D42
|texte= Parkinson's disease, cortical dysfunction, and alpha‐synuclein
}}
| This area was generated with Dilib version V0.6.23. |  |